Table 4.
AA and EET Pathways
| Measures | Placebo (n=16) | Febuxostat (n=16) | Febuxostat‐Rasburicase (n=16) | P Value | |||
|---|---|---|---|---|---|---|---|
| ANOVA | Placebo vs Febuxostat | Placebo vs Febuxostat‐Rasburicase | Febuxostat vs Febuxostat‐Rasburicase | ||||
| EET, pg/mLa | 44.8 (36.6; 65.0) | 55.7 (38.4; 75.2) | 45.8 (39.9; 70.6) | 0.003 | 0.015 | 1.0 | 0.15 |
| AA, ng/mL | 10 657.3±956.5 | 12 235.2±1235.7 | 11 689.0±877.8 | 0.2 | ··· | ··· | ··· |
| EET/AA, ×10−6 a | 4.7 (2.9; 7.1) | 4.4 (2.6; 7.0) | 4.8 (2.6; 6.6) | 0.8 | ··· | ··· | ··· |
Data are given as mean±SEM or median (quartile 1; quartile 3). AA indicates arachidonic acid; EET, epoxyeicosatrienoic acid.
a
Not normally distributed.